Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2008

View Archived Issues

Continuous HBV suppression seen with tenofovir over 96 weeks

EA-230 attenuates acute renal failure in vivo

Therapure and Biomedical sign agreement for production of iron chelating agent for thalassemia

Recent Teva and Roche patents disclose new antipsychotic agents

Novel CETP inhibitors for lipoprotein disorders disclosed in recent Kowa patent

Recent Auspex and Novartis patents impart new therapeutic agents for gastrointestinal disorders

Oxford Genome Sciences changes name to Oxford BioTherapeutics

GeoVax commences phase IIa HIV/AIDS vaccine human trials

Auxilium and Ferring sign European license agreement for Testim testosterone gel

Takara Bio to supply UCLA with RetroNectin for phase II clinical trial of advanced melanoma

Alkermes regains U.S. commercialization rights to Vivitrol from Cephalon

Johnson & Johnson to acquire Mentor for approximately USD 1.07 billion

sPLA2 inhibition beneficial in animal models of spinal cord injury

Novel papain-like protease inhibitor with antiviral activity against SARS identified

S*BIO advances SB-1518 into phase I/II for chronic idiopathic myelofibrosis

Addex initiates phase IIb trial of ADX-10059 as add-on therapy to PPIs in GERD

Genaera initiates phase Ib trial of MSI-1436 in overweight and obese type 2 diabetics

Enobia doses first infant patient in ERT trial of ENB-0040 for hypophosphatasia

Camurus reports phase IIa results for CAM-2032 in prostate cancer

European Commission approves Erbitux for first-line use in head and neck cancer

GSK and Theravance present phase IIb data for GW-642444 in asthma

XenoPort reports top-line results from phase II clinical trial of XP-19986 for GERD

PRT-060128 reduces platelet reactivity in CAD patients not responding to clopidogrel

Effects on systolic ejection time, fractional shortening seen with CK-1827452 in heart failure

Lilly presents dual CCR2/CCR5 antagonist as antidiabetes, antiobesity candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...